If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-11. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
== O == Severo Ochoa (1905–1993). Spanish and American biochemist at New York University, major contributor to elucidating the genetic code. Nobel Prize in Physiology or Medicine (1959). Member Natl. Acad. Sci. USA. Alexander George Ogston FRS (1911–1996). British biochemist at Oxford University, known for the three-point attachment explanation of how an achiral substance can have a chiral product in the tricarboxylate cycle. Reiji Okazaki (1930–1975). Japanese molecular biologist at Nagoya University, known for discovering Okazaki fragments, an essential step for understanding DNA replication. Tsuneko Okazaki (b. 1933). Japanese molecular biologist at Nagoya University, known for discovering Okazaki fragments, an essential step for understanding DNA replication. L'Oréal-UNESCO Award for Women in Science. Joan Oró (1923–2004). Spanish biochemist at the University of Houston. Prominent for studies of the origin of life. Muriel Wheldale Onslow (1880–1932). British biochemist at Cambridge University, pioneer in biochemical genetics who worked on petal colour in flowers. Alexander Oparin, (1894–1980). Soviet biochemist at Moscow State University, known for his theory on the origin of life in coacervates. Full Member of the USSR Academy of Sciences. Mary Osborn (b. 1940). English cell biologist at the University of Göttingen known for developing techniques for determining protein molecular masses. Mary Jane Osborn (1927–2019). American biochemist at the University of Connecticut, who worked on lipopolysaccharides, and discovered the mechanism of action of methotrexate.
== Retirement (1970–1979) == Even though Ron "retired" from live performances, he continued to hone his guitar skills, acquiring influences from then current Hard rock, Southern rock and Heavy metal acts like Deep Purple (guitarist Ritchie Blackmore being a seminal influence), Judas Priest, Styx, Blue Öyster Cult, Lynyrd Skynyrd and Rush. Ron began recording his own demos at home and studied the keyboard as well.
The Australian National University Act received royal assent on 1 August 1946. The act created the Australian National University (ANU), and gave the medical research institute the name "John Curtin School of Medical Research". H. C. "Nugget" Coombs, an economist and head of the Department of Post-War Reconstruction, accompanied the Prime Minister, Ben Chifley, on an official visit to the UK as his principal advisor. Coombs met with Florey in Oxford in May 1946. They agreed that the success of the new university would depend on the quality of faculty they could attract, and he wanted four eminent scholars to lead the four research schools: Florey for medicine, Mark Oliphant for physics, Keith Hancock for history, and Raymond William Firth for Pacific studies. Each received an official invitation in April 1947, and they were invited to come to Canberra for consultation in December 1947 and January 1948. They would constitute an academic advisory committee, for which they would be paid £250 (equivalent to A$20,242 in 2022) plus £200 (equivalent to A$16,193 in 2022) expenses per annum. Since they were all located in the UK, a London office of the university was opened to provide liaison. Florey never moved to Canberra, but he did accept the position of acting director of the John Curtin School of Medical Research for a five-year term commencing in May 1948 in order to establish it. Brian Lewis had been appointed university architect, but Florey hired Stephen Welsh, the professor of architecture at Sheffield University.
In addition to regulating the experiments that were conducted, the guidelines also forbade the performance of other experiments. One such experiment was the cloning of recombinant DNAs derived from highly pathogenic organisms. In addition, neither the cloning of DNA containing toxin genes nor large-scale experiments using recombinant DNAs that were able to make products that were potentially harmful to humans, animals, or plants were allowed under the guidelines. These experiments were banned because the potential biohazards could not be contained by the then-current safety precautions.
Sources: en.wikipedia.org
Zenobi-Wong works in the area of tissue engineering, in particular for cartilage regeneration. She develops functional biomaterials which mimic the extracellular matrix. The biofabrication techniques used to develop these materials include electrospinning, casting, two-photon polymerization and bioprinting. Zenobi-Wong holds four licensed patents in the fields of tissue engineering, tissue engineering techniques, and gene expression assays. She was one of the originators of the MSc Biomedical Engineering program at ETH Zürich, and developed several graduate level courses in tissue engineering and biomedical engineering. Zenobi-Wong currently serves as President of the Swiss Society for Biomaterials and Regenerative Medicine, and as secretary general of the International Society of Biofabrication. ETH Zürich Department of Health Sciences and Technology - Tissue Engineering and Biofabrication Group Marcy Zenobi-Wong publications indexed by Google Scholar
The impact of this ~10 km asteroid massively altered the 187Os/188Os signature of marine sediments at that time - the average extraterrestrial 187Os/188Os of ~0.13 and the huge amount of Os this impact contributed (equivalent to 600,000 years of present-day riverine inputs) lowered the global marine 187Os/188Os value of ~0.45 to a minimum of ~0.2. Os isotope ratios may also be used as a signal of anthropogenic impact. The same 187Os/188Os ratios that are common in geological settings may be used to gauge the addition of anthropogenic Os through things like catalytic converters. While catalytic converters have been shown to drastically reduce the emission of NOx and CO, they are introducing platinum group elements (PGE) such as Os, to the environment. Other sources of anthropogenic Os include combustion of fossil fuels, smelting chromium ore, and smelting of some sulfide ores. In one study, the effect of automobile exhaust on the marine Os system was evaluated. Automobile exhaust 187Os/188Os has been recorded to be ~0.2 (similar to extraterrestrial and mantle derived inputs). The effect of anthropogenic Os can be seen best by comparing aquatic Os ratios and local sediments or deeper waters. Surface waters thought to be affected have depleted values compared to deep ocean and sediments by a ratio larger than can be explained by cosmic inputs. The alpha decay of 184Os into 180W (with a rate perhaps large enough for detection) has been proposed as a radiometric dating method for osmium-rich rocks or for differentiation of a planetary core.
As a result, the more interesting possibilities remain on the table and the mystery of the tension deepens." Research suggests that replacing half of the beef, chicken, dairy and pork products consumed globally with plant-based alternatives by 2050 could reduce the amount of land used by agriculture by almost a third, bring deforestation for agriculture nearly to a halt, help restore biodiversity through rewilding the land and reduce GHG emissions from agriculture by 31%, paving a clearer path to reaching climate and biodiversity targets. A separate study (6 Sep) using a global food system model suggests that net-negative greenhouse gas emissions could be possible in a sustainable food system achievable with full global deployment of diverse interventions, with the most promising options including hydrogen-powered fertilizer production, livestock feeds, organic and inorganic soil amendments, agroforestry, sustainable seafood harvesting practices, and adoption of flexitarian diets. 18 September A new palm oil substitute called PALM-ALT is presented by researchers. The plant-based ingredient is shown to be 70% better for the environment than conventional palm oil and is described as "the holy grail to replace it". The Linac Coherent Light Source at the SLAC National Accelerator Laboratory is upgraded to LCLS-II and successfully demonstrates its first X-rays, which are fired 8,000 times faster and are 10,000 times brighter than the previous version.
== Applications == Surfactants are widely used due to their ability to modify surface and interfacial properties, making them relevant in processes involving the interaction of hydrophobic and hydrophilic substances. Their amphiphilic nature—containing both hydrophilic and hydrophobic parts—enables them to bridge these otherwise immiscible components, thereby facilitating mixing and enhancing the efficiency of various physical and chemical transformations. This makes surfactants useful in numerous fields where control over interfacial interactions is relevant. Surfactants play an important role as cleaning, wetting, dispersing, emulsifying, foaming and anti-foaming agents in many practical applications and products, including detergents, fabric softeners, motor oils, emulsions, soaps, paints, adhesives, inks, anti-fogs, ski waxes, snowboard wax, in flotation, washing and enzymatic processes, and laxatives.
For small strains, the measure of stress that is used is the Cauchy stress while the measure of strain that is used is the infinitesimal strain tensor; the resulting (predicted) material behavior is termed linear elasticity, which (for isotropic media) is called the generalized Hooke's law. Cauchy elastic materials and hypoelastic materials are models that extend Hooke's law to allow for the possibility of large rotations, large distortions, and intrinsic or induced anisotropy. For more general situations, any of a number of stress measures can be used, and it is generally desired (but not required) that the elastic stress–strain relation be phrased in terms of a finite strain measure that is work conjugate to the selected stress measure, i.e., the time integral of the inner product of the stress measure with the rate of the strain measure should be equal to the change in internal energy for any adiabatic process that remains below the elastic limit.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.